Document is current
Any future updates will be listed below
-
Authors
Buschur, Kristina L.
Riley, Craig
Saferali, Aabida
Castaldi, Peter
Zhang, Grace
Aguet, Francois
Ardlie, Kristin G.
Durda, Peter
Craig Johnson, W.
Kasela, Silva
Liu, Yongmei
Manichaikul, Ani
Rich, Stephen S.
Rotter, Jerome I.
Smith, Josh
Taylor, Kent D.
Tracy, Russell P.
Lappalainen, Tuuli
Graham Barr, R.
Sciurba, Frank
Hersh, Craig P.
Benos, Panayiotis V.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32HL144442, R01HL142028, R01HL121270, R01HL125583, R01HL159805)
- License Information
-
More Information
Article History
Received: 22 September 2022
Accepted: 5 January 2023
First Online: 25 January 2023
Declarations
:
: All COPDGene and MESA study participants provided written informed consent. Each study center obtained institutional review board (IRB) approval.
: Not applicable.
: Peter Castaldi reports receiving grant support from GSK and Bayer and personal fees from GSK and Novartis. Tuuli Lappalainen is an advisor to Goldfinch Bio, Variant Bio, and GSK, and has equity in Variant Bio. Craig Hersh reports grant support from Bayer, Boehringer-Ingelheim, Novartis, and Vertex, and personal fees from Astra-Zeneca and Takeda.
: Information about how to access the human cohort data can be found at and .
